Institute of Ocular Medicine
The Institute of Ocular Medicine is an institute that differentiates itself from other eye institutes in the nation and world. The major function of the IOP is to invent new drugs for eye diseases, including glaucoma, cataracts, ischemic retinopathy, uveitis, dry eyes, myopia and age-related macular degeneration (AMD). The Institute of Ocular Medicine published the Journal of Ocular Pharmacology and Therapeutics, the official journal of the Association of Ocular Pharmacology and Therapeutics, from 1985 to 2004, and Ophthalmic Toxicology in 1992 and 1999.
The Institute of Ocular Medicine is active in research, inventing new drugs, elucidating drug action mechanisms, improving formulations for better bioavailability of new and old drugs, and researching the safety of effective eye drugs. New drugs developed in the IOP include Timolol, dopamine antagonists, serotonin antagonists, carbonic anhydrase inhibitors, and cholinergic drugs for glaucoma treatment, synthetic CK-compounds, as well as natural compounds, such as osthole, matrine, etc., for uveitis and various types of inflammation. The IOP is developing new drugs for the treatment of dry-AMD, which lacks any drugs available for treatment at the present time.
Traditionally, ocular hypertension was considered to be the major cause of glaucoma. A new factor, ocular blood flow, was introduced in the 1980s in the IOP, which changes the concept of glaucoma etiology and improves the diagnosis and treatment of glaucoma, the leading cause of blindness.
The Institute of Ocular Medicine collaborating internationally with numerous researchers in various institutions, including: Dr. T. Okawara of Kumarnoto University in Japan; Drs. Z.D. Min and Y.H. Zhang of China Pharmaceutical University in China; Dr. Q.S. Yao of Nanjing Institute of Materia Medica in China; Drs. T.S. Hu and Y.H. Zou of Peking Union Medical College in China; Dr. S.J. Hong of Kaohsiung Medical College in Taiwan; and Dr. P.T. Hung of National Taiwan University Medical School in Taiwan. These international collaborations have resulted in the development of new eye drugs, as well as non-eye drugs for the treatment of cardiac arrhythmias, ischemic strokes, and systemic inflammatory diseases.
The Institute of Ocular Medicine not only emphasizes basic research but also clinical applications and usefulness to improve the welfare of humans. Because of the aging of the general population, maintenance of healthy eye sight becomes more and more important, both now and in the future. The major mission of the Institute of Ocular Medicine is to insure the healthy vision of seniors so they can enjoy the later years of their lives.
Dr. Bo Xuan earned her MD with honors from Nanjing Medical University (NMU) in 1984. She served on the faculty at the Department of Pharmacology at NMU from 1984 to 1996 before being recruited to the Institute of Ocular Pharmacology (IOP). Xuan advanced rapidly from research associate to assistant research professor in 1999. During her tenure at the IOP, she has published 20 papers and has successfully converted to clinician in 2003. Her research accomplishments in ocular pharmacology and therapeutics include, but are not limited to, the treatment of glaucoma, age related macular degeneration (AMD), cataracts, ischemic retinopathy, dry eye syndrome, uveitis and myopia. Further, she has participated in the clinical project of systemic delivery of glucagon to diabetic patients through the eyes. Currently she works as a physician in the Student Health Services of Texas A&M University and as a clinical assistant professor of IOP in the Texas A&M College of Medicine.
George C.Y. Chiou, PhD
PhD in Pharmacology, Vanderbilt University, 1967. Postdoctoral Research in Autonomic Pharmacology, University of Iowa Medical School.
Paul C. Brandt, PhD
PhD, Biochemistry, University of Kentucky, 1990. Postdoctoral, Psychobiology, University of California - Irvine.
- Beauregard, C., Brandt, P.C. andchiou, G.C.Y. Induction of nitric oxide synthase and over-production of nitric oxide by interleukin-lb in cultured lacrimal gland acinar cells.Exp. Eye Res. 77: 109-1 14 (2003).
- Zou, Y.H. and Chiou, G.C.Y. Pharmacological therapy in age-related macular degeneration (AMD) Internatl J. Ophthalmol. 5:8-18 (2005).
- Xuan, B., McClellan, D.A., Moore, R., and Chiou, G.C.Y. Alternative delivery of insulin via eyedrops. Diabetes Technology & Therapeutics, 7:695-698 (2005).
- Xu, X.R. Zou, Y.H., and Chiou, G.C.Y. The effect of D-timolol and L-timolol on rat experimental choroidal neovascularization (CNV) in vivo and endothelial cells in vitro.International J Ophthalmol., 5:831-835 (2005).
- Zou, Y .H., Xu X.R., and Chiou G.C.Y. Effort of interleukin- 1 blockers, CK112 and Ck116 on rat experimental choroidal neovascularization (CNV) in vivo and endothelialcells culture in vitro. J. Ocular Pharrnacol. Therap., 22:19-25 (2006).
- Zou Y. H. and Chiou G.C.Y. Apigenin inhibits laser-induced choroidal neovascularization and regulates endothelial cell function. J. Ocular Pharmacol. Therap.22:425-430 (2007).
- Zou, Y.H, Jiang, W., and Chiou, G.C.Y. Affect of Tetramethyl pyrazine on rat experimental choroidal neovascularization in vivo and endothelial cell culture in vitro.Current Eye Res. 32:71-75 (2007).
- Jiang, W., KO, W.C., Hsiao, S.H., and Chiou, G.C.Y. Effect of Z,E-butylidedephthalide on experimental choroidal neovascularization in rat iind ocular blood flow in rabbits.International J. Ophthalmol., 7: 1-7 (2007).